Literature DB >> 2746759

Local and systemic effects of chronic intracavernous injection of papaverine, prostaglandin E1, and saline in primates.

S R Aboseif1, J Breza, R J Bosch, F Benard, C G Stief, W Stackl, T F Lue, E A Tanagho.   

Abstract

To compare the local and systemic effects of chronic intracavernous injection of papaverine, prostaglandin E1, and saline on erectile tissue, eight pigtail monkeys underwent 75 injections over a nine-month period. Monkeys were divided into three groups; each group received papaverine (10 mg.), prostaglandin E1 (20 micrograms.), or saline (one ml.). The erectile response was closely observed for two hours after each injection to monitor the onset, degree, and duration of erection. Liver function tests were performed every three months to detect early systemic metabolic changes. After sacrifice, the simian penises were perfused in situ and examined histologically with both light and electron microscopy. Papaverine resulted in an initially strong erectile response, but this was maintained throughout the length of the study in only two monkeys. In contrast, prostaglandin E1 resulted in tumescence that was maintained in all monkeys over the nine-month period. In addition, the papaverine group had elevated liver enzymes and significant histologic changes with loss of normal architecture on both light and electron microscopy. The other two groups showed only minimal histologic changes or none.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2746759     DOI: 10.1016/s0022-5347(17)38773-6

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

Review 1.  Current concepts in the treatment of genitourinary tract disorders in the older individual.

Authors:  A Atala; M Amin
Journal:  Drugs Aging       Date:  1991-05       Impact factor: 3.923

Review 2.  Self-administration in the pharmacological treatment of impotence.

Authors:  F Bénard; T F Lue
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

Review 3.  Intracavernous prostaglandin E1 in erectile dysfunction.

Authors:  O I Linet; L L Neff
Journal:  Clin Investig       Date:  1994-01

Review 4.  Drug-induced male sexual dysfunction. An update.

Authors:  G B Brock; T F Lue
Journal:  Drug Saf       Date:  1993-06       Impact factor: 5.606

Review 5.  Treating erectile dysfunction in renal transplant recipients.

Authors:  John M Barry
Journal:  Drugs       Date:  2007       Impact factor: 9.546

6.  Penile erections induced by vasoactive intestinal peptide and sodium nitroprusside.

Authors:  R Wang; T R Higuera; S C Sikka; R K Minkes; J A Bellan; P J Kadowitz; F R Domer; W J Hellstrom
Journal:  Urol Res       Date:  1993-01

Review 7.  Intracavernous alprostadil. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in erectile dysfunction.

Authors:  A P Lea; H M Bryson; J A Balfour
Journal:  Drugs Aging       Date:  1996-01       Impact factor: 3.923

8.  Evaluation of the sensitivity of different doses of vasoactive drugs in diagnosing erectile dysfunction in impotent patients: a prospective case-control study.

Authors:  Shady Zaki Said; Taha Abdel Nasser; Mohammad Ayad; Ahmad Tarek Motawi
Journal:  Cent European J Urol       Date:  2021-02-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.